Injection of one shot effect more than half a year! HIV treatment welcomes new candidates for long-acting drugs.

Today, a new paper published online in nature, a leading academic journal, presents the potential for long-term treatment of HIV infection with a new small molecule drug developed by the biopharmaceutical company Gilead SciencesPreliminary clinical studies showed that after a single dose of the drug, hiv-infected people had reduced viral load in the body, and the drug remained active in the body after more than 6 months of injectionstudy authors point out in their paper that daily oral oral antiviral "cocktail" therapy provides a life-saving treatment for millions of people living with HIV, but there are still some who are resistant to multiple drugs, reducing the effectiveness of the treatmentIf, for some reason, patients are unable to adhere to daily medication, not only may the virus in the body return, but the risk of drug resistance will increase, not conducive to treatmentthat's why researchers are working to develop new long-acting drugs that will give patients with HIV-resistant strains more treatment options, and significantly reduce the frequency of medication, helping patients stick to treatment optionsbeforeintroduce the drugs in this paper, let's briefly introduce HIVAmong the virus particles, there is a unique cone protein shell called the HIV shellThe genome of the virus, along with reverse transcriptases and integration enzymes, is hidden in this shellThe shell is self-assembled by a shell protein that not only protects the genetic material of the virus, but also helps the virus's genes and enzymes to fit perfectly at all stages of HIV infection, thus producing the virus continuouslythe authors of the study, most small-molecule antiviral drugs for HIV work by interfering with the virus's reverse transcriptase or integrated enzymes, and the new drug, called GS-6207, is a different targetDesigned to bind the HIV shell protein closely, this small molecule can interfere with the assembly of the shell and disrupt its functionin cell experiments, the scientists found that the small molecule had a wide range of activity against more than 20 HIV strains tested, effectively inhibited the replication of the virus, and ec50 was 105 pM in MT-4 cells infected with HIV-1, making them more potent than other approved antiretroviral drugsIn addition, GS-6207 and other antiretroviral drugs can be used together to produce synergies, which researchers believe can be an ideal complement to "cocktail therapy."followed by preliminary clinical trialsIn a single-dose study of randomized, double-blind and placebo-controlled cases of 40 healthy individuals, the researchers showed overall safety and good tolerance by injecting the drug with subcutaneous injectionsMoreover, GS-6207 showed slow, sustained drug release, with only one injection, and after more than six months the drug remained active in the body later, the researchers conducted phase 1 clinical trials in 32 patients infected with HIV-1 but not treated The results showed that after 9 days of single-dose administration, the viral load in the patient's body decreased, although it was not completely removed at the end of the paper, the researchers concluded that GS-6207, a first-in-class HIV-1 shell inhibitor, exhibited good safety, prolonged pharmacokinetic exposure, and the antiviral effects observed in humans, and could continue clinical development for long-term treatment of HIV infection The study authors also said that because of the need for frequent administration, the small molecule drug could become a candidate for HIV prevention in risk groups, but that this needs to be tested in follow-up studies we look forward to positive results from this innovative treatment in subsequent clinical studies that will ultimately benefit more people living with HIV-1 .